资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、创新 药、抗癌药物、抗癌治癌、猴痘概念等。 来源：新浪证券-红岸工作室 9月25日，君实生物盘中上涨2.18%，截至09:35，报42.58元/股，成交5648.08万元，换手率0.17%，总市 值437.16亿元。 资金流向方面，主力资金净流入31.36万元，特大单买入306.69万元，占比5.43%，卖出0.00元，占比 0.00%；大单买入1392.73万元，占比24.66%，卖出1668.05万元，占比29.53%。 君实生物今年以来股价涨55.80%，近5个交易日跌6.89%，近20日跌3.16%， ...

Core Viewpoint - Microchip Biotech's stock has shown significant growth this year, with a 76.80% increase, despite recent fluctuations in trading performance [1][2]. Group 1: Stock Performance - On September 24, Microchip Biotech's stock rose by 2.05%, reaching 32.85 CNY per share, with a trading volume of 1.28 billion CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 13.396 billion CNY [1]. - Year-to-date, the stock has increased by 76.80%, with a slight decline of 0.09% over the last five trading days and an 8.03% drop over the last 20 days, while it has risen by 15.95% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Microchip Biotech reported a revenue of 407 million CNY, representing a year-on-year growth of 34.56%, and a net profit attributable to shareholders of 29.592 million CNY, which is a 172.16% increase compared to the previous year [2]. Group 3: Company Overview - Microchip Biotech, established on March 21, 2001, and listed on August 12, 2019, is located in the Zhigu Industrial Park, Nanshan District, Shenzhen, Guangdong Province. The company focuses on providing affordable, urgently needed innovative molecular entity drugs for patients [1]. - The company's revenue composition includes 97.80% from product sales, 1.81% from other supplementary sources, 0.27% from technology licensing, and 0.13% from other sources [1]. - Microchip Biotech operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in concepts such as monkeypox, biomedicine, innovative drugs, and cancer treatment [1].

Core Viewpoint - The stock of BeiGene has shown significant volatility, with a year-to-date increase of 92.45% but a recent decline in the last five trading days, indicating potential market fluctuations and investor sentiment shifts [2]. Group 1: Stock Performance - As of September 24, BeiGene's stock price reached 309.88 CNY per share, with a market capitalization of 477.43 billion CNY [1]. - The stock has experienced a 1.10% decline over the last five trading days, while it has increased by 25.96% over the past 20 days and 33.79% over the last 60 days [2]. - The company has appeared on the stock market's "龙虎榜" once this year, with the latest occurrence on September 2 [2]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, reflecting a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, which is a 115.63% increase compared to the previous year [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for BeiGene was 23,300, a decrease of 3.90% from the previous period, with an average of 4,976 shares held per shareholder, an increase of 4.11% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by 中欧医疗健康混合A and a decrease in holdings by 万家优选 and 工银前沿医疗股票A [3].

Core Viewpoint - Zai Lab's stock price has shown significant growth this year, with a 72.06% increase, despite recent fluctuations in trading volume and net capital outflow [1][2]. Group 1: Stock Performance - As of September 24, Zai Lab's stock price reached 107.21 CNY per share, with a market capitalization of 28.379 billion CNY [1]. - The stock has increased by 1.99% over the last five trading days and 4.60% over the last twenty days, while it has decreased by 3.97% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Zai Lab reported a revenue of 376 million CNY, representing a year-on-year growth of 56.07% [2]. - The company recorded a net loss attributable to shareholders of 72.8035 million CNY, which is a decrease of 9.42% compared to the previous period [2]. Group 3: Shareholder Information - As of June 30, 2025, Zai Lab had 8,795 shareholders, an increase of 16.75% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 14.35% to 30,097 shares [2]. Group 4: Institutional Holdings - Notable institutional shareholders include China Europe Medical Health Mixed A, which increased its holdings by 2.6875 million shares, and new entrants like Huatai-PineBridge Innovation Medicine Mixed A and Fortune Precision Medical Flexible Allocation Mixed A [2].

9月24日，益方生物盘中上涨2.05%，截至10:09，报33.39元/股，成交1.20亿元，换手率0.88%，总市值 193.10亿元。 资金流向方面，主力资金净流出82.25万元，特大单买入316.54万元，占比2.64%，卖出318.33万元，占 比2.66%；大单买入1941.58万元，占比16.20%，卖出2022.04万元，占比16.87%。 益方生物今年以来股价涨151.05%，近5个交易日跌3.86%，近20日跌13.39%，近60日涨3.37%。 今年以来益方生物已经3次登上龙虎榜，最近一次登上龙虎榜为7月11日，当日龙虎榜净买入6887.06万 元；买入总计4.80亿元 ，占总成交额比44.57%；卖出总计4.11亿元 ，占总成交额比38.17%。 益方生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、抗癌药物、抗 癌治癌、年度强势、中盘等。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室，成 立日期2013年1月11日，上市日期2022年7月25日，公司主营业务涉及创新药物的研发、生产和销售。主 营业务收入构成为 ...

Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on May 29, 2002, and listed on June 3, 2010. The company specializes in the development, production, and sales of large-volume parenteral solutions [1][2] - The main business revenue composition includes: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1] Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2] - Since its A-share listing, the company has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3] Stock Market Activity - On September 24, Kelun Pharmaceutical's stock price increased by 2.00%, reaching 37.69 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 0.22%. The total market capitalization is 60.231 billion yuan [1] - Year-to-date, the stock price has risen by 28.07%, with a 2.03% increase over the last five trading days, 2.14% over the last twenty days, and 6.14% over the last sixty days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where the net buying amount was 31.8792 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders is 34,200, an increase of 2.55% from the previous period. The average circulating shares per person decreased by 2.49% to 38,138 shares [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]

9月24日，艾迪药业盘中上涨2.20%，截至09:52，报14.87元/股，成交2932.32万元，换手率0.47%，总市 值62.57亿元。 艾迪药业今年以来股价涨89.19%，近5个交易日跌2.11%，近20日跌11.86%，近60日涨4.79%。 机构持仓方面，截止2025年6月30日，艾迪药业十大流通股东中，鹏华医药科技股票A（001230）位居 第五大流通股东，持股680.55万股，持股数量较上期不变。招商行业精选股票（000746）位居第九大流 通股东，持股393.12万股，为新进股东。广发价值核心混合A（010377）位居第十大流通股东，持股 393.10万股，为新进股东。 资料显示，江苏艾迪药业集团股份有限公司位于江苏省扬州市邗江区新甘泉西路69号，成立日期2009年 12月15日，上市日期2020年7月20日，公司主营业务涉及探索、研发和销售创新性化学药物以及人源蛋 白产品。主营业务收入构成为：人源蛋白41.11%，新药35.69%，诊断设备、试剂及其他13.62%，普药 9.47%，其他(补充)0.11%。 责任编辑：小浪快报 截至6月30日，艾迪药业股东户数1.19万，较上期增加34.4 ...

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, focusing on the research and commercialization of monoclonal antibodies and therapeutic proteins [7] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a year-on-year increase of 36.01% [8] Group 2: Product Pipeline and Innovations - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - Junshi Biosciences is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2] - The company is also collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3] Group 3: Market Performance and Investor Sentiment - On September 23, Junshi Biosciences' stock fell by 4.26%, with a trading volume of 755 million yuan and a market capitalization of 42.69 billion yuan [1] - The stock has seen a net outflow of 48.4 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5] - The average trading cost of the stock is 41.93 yuan, with the stock price approaching a resistance level of 42.00 yuan, suggesting potential volatility [6]

诺诚健华今年以来股价涨119.22%，近5个交易日跌1.43%，近20日跌6.85%，近60日涨4.26%。 机构持仓方面，截止2025年6月30日，诺诚健华十大流通股东中，中欧医疗健康混合A（003095）位居 第六大流通股东，持股1304.78万股，相比上期增加398.07万股。富国精准医疗灵活配置混合A （005176）位居第七大流通股东，持股1258.20万股，持股数量较上期不变。鹏华医药科技股票A （001230）位居第八大流通股东，持股1020.21万股，相比上期减少501.14万股。易方达医疗保健行业混 合A（110023）位居第九大流通股东，持股918.57万股，为新进股东。汇添富创新医药混合A （006113）位居第十大流通股东，持股760.38万股，为新进股东。兴全合润混合A（163406）、平安医 疗健康混合A（003032）退出十大流通股东之列。 资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期 2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生 物医药的研发、生产和商业化的中国公司。该公 ...

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established on November 3, 1998, and listed on September 10, 2009. The company is located at 37th Floor, Green View Plaza, Chegongmiao, Shenzhen, Guangdong Province. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1][2]. Financial Performance - For the first half of 2025, Xinlitai achieved operating revenue of 2.131 billion yuan, representing a year-on-year growth of 4.32%. The net profit attributable to shareholders was 365 million yuan, with a year-on-year increase of 6.10% [2]. - Since its A-share listing, Xinlitai has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3]. Stock Performance - As of September 23, Xinlitai's stock price was 50.84 yuan per share, with a market capitalization of 56.677 billion yuan. The stock has increased by 67.07% year-to-date, but has seen a decline of 3.58% over the past five trading days and 4.24% over the past 20 days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on June 17, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of June 30, 2025, Xinlitai had 24,000 shareholders, a decrease of 0.79% from the previous period. The average number of circulating shares per shareholder was 46,403, an increase of 0.80% [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with significant changes in their holdings [3].